DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» BeiGene
BeiGene
Mirati's Clinical Programs
Beigene, Ltd. 百濟神州有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 06160)
Hon55 2630.Pdf
Abstract EP783 MARGINAL ZONE LYMPHOMA (MAGNOLIA STUDY)
Beigene, Ltd. (Incorporated in the Cayman Islands with Limited Liability and Trading As “百濟神州”Or“百濟神州有限公司”) (Stock Code: 06160)
WCLC 2020 Faculty Chairs Disclosure Summary
Beigene, Ltd. 百濟神州有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 06160)
Sustainability at Beigene 2020 Environmental, Social, and Governance (ESG) Report Beigene 2020 ESG Report
Clinigen Launches Managed Access Program with Beigene for Zanubrutinib
Puretech Announces Clinical Trial and Supply Agreement with Beigene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-To-Treat Solid Tumors
Novartis Turns to Beigene for a PD-1 Blocker
Summary Introduction Study Objectives Methods Results
Beigene Corporate Presentation
Beigene Corporate Brochure
Leap Therapeutics and Beigene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Acceleration of Biopharma Partnering Activity Into China
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Clinical Development of Beigene TIGIT and OX40 Targeted Therapies
Top View
Beigene, Ltd. 百濟神州有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 06160)
1 | P a G E Beigene Launches BRUKINSA® (Zanubrutinib) In
Novartis Expands Oncology Pipeline with In-Licensing of Tislelizumab from Beigene
Immunotherapy of Ipilimumab And
Atreca, Beigene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19
Novartis Financial Results Q1 2021 – English
Beigene, Ltd. Form 8-K Current Event Report Filed 2021-08-05
Novartis Strengthens Oncology Pipeline with Successful Closing of Tislelizumab In-Licensing
Disclosure Summary
Beigene, Ltd. 百濟神州有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 06160)
Novartis Q2 2021 Condensed Interim Financial Report
Beigene Press Release BRUKINSA WM Approval US 9.1.21
Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with Beigene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers
Review Nivolumab for the Treatment of Esophageal Squamous Cell
Assembly Biosciences and Beigene Announce License And
Download Pipeline
Beigene, Ltd. 百濟神州有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 06160)
Dreyling BGB-3111 306 ASCO Poster 2020.Pdf